University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne

Genetic and phenotypic spectrum associated with IFIH1 gain-of-function (2020) Rice G, Park S, Gavazzi F, Adang LA, Ayuk LA, Van Eyck L, Seabra L, et al. Journal article De novo variants in SNAP25 cause an early-onset developmental and epileptic encephalopathy (2020) Kloeckner C, Sticht H, Zacher P, Popp B, Babcock HE, Bakker DP, Barwick K, et al. Journal article Quantitative 1H and 23Na muscle MRI in Facioscapulohumeral muscular dystrophy patients (2020) Gerhalter T, Marty B, Gast L, Porzelt K, Heiß R, Uder M, Schwab S, et al. Journal article Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020) Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, et al. Journal article, Review article Advances in Understanding High-Mass X-ray Binaries with INTEGRALand Future Directions (2019) Kretschmar P, Furst F, Sidoli L, Bozzo E, Alfonso-Garzon J, Bodaghee A, Chaty S, et al. Journal article Other Causes of Limbal Stem Cell Deficiency Reply (2019) Deng SX, Borderie V, Chan CC, Dana R, Figueiredo FC, Gomes JAP, Pellegrini G, et al. Journal article, Letter Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, et al. Journal article Clinical Integration of Automated Processing for Brain Quantitative Susceptibility Mapping: Multi-Site Reproducibility and Single-Site Robustness (2019) Spincemaille P, Liu Z, Zhang S, Kovanlikaya I, Ippoliti M, Makowski M, Watts R, et al. Journal article Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis (2019) Kremer A, Le Cleac'H A, Lemoinne S, Wolf K, De Chaisemartin L, Chollet-Martin S, Humbert L, et al. Journal article, Letter Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution